Patten & Patten Inc. TN Has $7.22 Million Stock Holdings in DexCom, Inc. $DXCM

Key Points

• Patten & Patten Inc. TN increased its stake in DexCom, Inc. by 6.1%, owning 82,738 shares valued at approximately $7.22 million as of the latest filing.
• Major financial analysts have issued a variety of ratings on DexCom, with an average target price of $97.00 and recommendations ranging from "buy" to "strong buy".
• DexCom recently reported earnings of $0.48 per share for the last quarter, exceeding estimates, along with a revenue of $1.16 billion, reflecting a 15.2% increase from the previous year.

Patten & Patten Inc. TN grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 82,738 shares of the medical device company's stock after purchasing an additional 4,780 shares during the quarter. Patten & Patten Inc. TN's holdings in DexCom were worth $7,222,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Horizon Investments LLC raised its position in DexCom by 2.2% during the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock valued at $383,000 after purchasing an additional 123 shares in the last quarter. Wedbush Securities Inc. raised its position in DexCom by 1.2% during the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock valued at $899,000 after purchasing an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. raised its position in DexCom by 3.2% during the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock valued at $407,000 after purchasing an additional 182 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its position in DexCom by 3.2% during the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company's stock valued at $411,000 after purchasing an additional 187 shares in the last quarter. Finally, Integrated Wealth Concepts LLC increased its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock worth $227,000 after buying an additional 196 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on DXCM shares. Argus started coverage on shares of DexCom in a report on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. Citigroup lowered their price target on shares of DexCom from $105.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday, October 7th. Mizuho upped their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Raymond James Financial boosted their price objective on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group reduced their price objective on shares of DexCom from $104.00 to $89.00 and set a "buy" rating on the stock in a research note on Wednesday, October 1st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average price target of $97.00.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company's stock, valued at $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,849 shares of company stock worth $564,733. Corporate insiders own 0.32% of the company's stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $65.41 on Thursday. The firm's 50-day moving average price is $73.79 and its 200-day moving average price is $77.54. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The firm has a market capitalization of $25.65 billion, a P/E ratio of 45.42, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business earned $0.43 earnings per share. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.